144 filed Jun 29, 2026 at 17:51 ET
Atlas Venture, a founding VC investor in Kymera Therapeutics, has filed two Form 144 notices to sell a combined 76,650 shares of common stock valued at approximately $8.3M (~0.09% of market cap). These filings follow a remarkable 9 consecutive days of heavy Atlas Venture selling (April through late June 2026) totaling over 1.6 million shares worth ~$157M, as disclosed in the same filing's recent transaction history. The selling is part of a systematic, pre-planned secondary distribution by a venture fund that owned the shares since a 2020 private placement and is well past its standard lock-up. While the 76,650 share amount is small relative to the prior week's pace (>1.4M shares sold June 17-26), the filings confirm Atlas continues to monetize its position in an orderly manner. This does not reflect management's view of the business, Kymera has 93% analyst buy ratings and a $9.4B market cap, but the persistent supply overhang is a real technical factor.